TELOHealthcare · Biotechnology

TELO Stock Forecast: Telomir Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$1.17

−0.85% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 10 Sept 2026 — in the weakest quartile.

Market cap

$81.2M

Ticker Nerd rank

15 / 100

Median analyst target

—

Analysts covering

Revenue$0.0

Operating income−$1.8M

Net income−$1.7M

Free cash flow−$1.0M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+0.9%

+3.5%

YTD

−12.0%

−14.6%

From 52W high

−39.4%

From 52W low

+27.3%

$0.92

$1.93

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

TELO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Telomir Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026

15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Volatility

Growth

Value

Revisions

Momentum

Issuance

Quality

Size (77): Smaller than most of the companies we track.

Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TELO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TELO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TELO appears on the weeks it earns a place.

Performance

TELO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Telomir Pharmaceuticals, Inc. returned −14.6% against +17.5% for the S&P 500, dividends included.

TELO vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TELO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Telomir Pharmaceuticals, Inc. (TELO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −3.6×
Price / sales: —
Price / book: 8.1×
EV / EBITDA: −7.3×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −213.1%
Return on assets: −122.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Telomir Pharmaceuticals, Inc. (TELO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Telomir Pharmaceuticals, Inc. has a market value of $81.2M and an enterprise value of $76.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$5.9M.
Free cash flow in the twelve months to 30 June 2026: −$4.9M.
Shares outstanding: 68.8M.
Trailing P/E: −3.6×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Telomir Pharmaceuticals, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

TELO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
TELOTelomir Pharmaceuticals, Inc.	$81.2M	15
OSTXOS Therapies, Inc.	$81.1M	32
RNXTRenovoRx, Inc.	$79.7M	38
MAIAMAIA Biotechnology, Inc.	$79.5M	22
VRCAVerrica Pharmaceuticals, Inc.	$85.0M	74
FBIOFortress Biotech, Inc.	$85.4M	79
MNOVMediciNova, Inc.	$85.5M	96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Telomir Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TELO news & analysis

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

GlobeNewsWire · 10 Aug 2026positive

Telomir Pharmaceuticals announced a peer-reviewed publication demonstrating that its candidate Telomir-Zn suppresses tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models. The announcement highlights the research findings from the publication.

Why it matters — This provides scientific validation for Telomir-Zn's therapeutic potential in two cancer types, which is directly relevant to the company's pipeline for TELO watchers.

FAQ

Frequently asked questions about TELO stock

How does Ticker Nerd's model rank TELO?

As at 10 Sept 2026, Telomir Pharmaceuticals, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (77 of 100).

What is the TELO stock forecast for 2030?

No analyst covering Telomir Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELO are extrapolating price history, which says nothing about the business.

How has TELO stock performed over the past year?

Telomir Pharmaceuticals, Inc. returned -14.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Telomir Pharmaceuticals, Inc. do?

What is the latest news on TELO?

The most recent item we track (GlobeNewsWire, 10 Aug 2026): "Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models". Telomir Pharmaceuticals announced a peer-reviewed publication demonstrating that its candidate Telomir-Zn suppresses tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models. The announcement highlights the research findings from the publication.

Company

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases. Its lead program centers on Telomir-1, an oral small molecule being studied for its ability to regulate metal ions and support cellular processes linked to telomere maintenance, epigenetic control, and inflammatory pathways. The company’s research spans a range of therapeutic areas, including oncology, metabolic disorders, ophthalmology, and neurodegenerative conditions. Telomir Pharmaceuticals, Inc. positions its platform around targeting underlying mechanisms rather than isolated symptoms, with current work aimed at advancing therapies for conditions such as triple-negative breast cancer, Wilson’s disease, type 2 diabetes, age-related macular degeneration, Alzheimer’s disease, and Progeria. The company is headquartered in Tampa, Florida.

CEO Mr. Erez Aminov · 1 employees · United States · https://telomirpharma.com